Wunderz Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 20-12-2024
- Paid Up Capital ₹ 1.69 M
as on 20-12-2024
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
as on 20-12-2024
- Satisfied Charges ₹ 4.50 M
as on 20-12-2024
- Revenue 9.09%
(FY 2015)
- Profit 5.31%
(FY 2015)
- Ebitda 11.22%
(FY 2015)
- Net Worth 8.55%
(FY 2015)
- Total Assets 16.69%
(FY 2015)
About Wunderz Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.69 M.
The company currently has active open charges totaling ₹0.50 M. The company has closed loans amounting to ₹4.50 M, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Pillai, Pradeep Radhakrishnannair, Gogi George, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232KL2007PTC020811
- Company No.
020811
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 May 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Wunderz Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Pillai  | Managing Director | 18-May-2007 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pradeep Radhakrishnannair | Director | 29-Mar-2016 | Current |
| Gogi George | Director | 03-May-2018 | Current |
| Rias Abdulkareem | Director | 03-May-2018 | Current |
Financial Performance of Wunderz Pharmaceuticals.
Wunderz Pharmaceuticals Private Limited, for the financial year ended 2015, experienced modest growth in revenue, with a 9.09% increase. The company also saw a slight improvement in profitability, with a 5.31% increase in profit. The company's net worth moved up by a moderate rise of 8.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wunderz Pharmaceuticals?
In 2017, Wunderz Pharmaceuticals had a promoter holding of 97.18% and a public holding of 2.82%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 31 Mar 2014 | ₹0.50 M | Open |
The Karur Vysya Bank Creation Date: 17 May 2011 | ₹3.00 M | Satisfied |
The Dhanalakshmi Bank Ltd Creation Date: 14 Oct 2009 | ₹1.00 M | Satisfied |
How Many Employees Work at Wunderz Pharmaceuticals?
Wunderz Pharmaceuticals has a workforce of 23 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wunderz Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wunderz Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
